Positioning of HIV-protease inhibitors in clinical practice.
暂无分享,去创建一个
[1] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[2] D. Richman. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.
[3] J. Baril,et al. Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks , 2009, HIV clinical trials.
[4] Marilyn M. Wagener,et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .
[5] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[6] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] A. Antinori,et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) , 2002, AIDS.
[8] Z. Fox,et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. , 2003, The Journal of infectious diseases.
[9] J. Lange. A Rational Approach to the Selection and Sequencing of Nucleoside/Nucleotide Analogues: A New Paradigm , 2000, Antiviral therapy.
[10] D. Pillay,et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Dale J. Kempf,et al. Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia , 2002, Antimicrobial Agents and Chemotherapy.
[12] N. Parkin,et al. Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors , 2003, Antimicrobial Agents and Chemotherapy.
[13] J. van Lunzen,et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 , 2008, AIDS.
[14] A. Luber,et al. Open Access Journal of the International Aids Society Genetic Barriers to Resistance and Impact on Clinical Response , 2005 .
[15] J. Molina,et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study , 2008, The Lancet.
[16] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[17] J. Hammond,et al. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients , 2008, Journal of acquired immune deficiency syndromes.
[18] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[19] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[20] B. Gazzard,et al. A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial , 2005, Antiviral therapy.